Three weeks of low-dose rituximab was found to prevent relapses and disability progression in NMOSD patients, without serious side effects.| Neuromyelitis News
Off-label rituximab significantly reduces the risk of relapse and lessens disability in most NMOSD patients, a long-term study showed.| Neuromyelitis News